Would you offer adjuvant immunotherapy to patients with stage II-III NSCLC who achieved a pathologic complete response from 3 cycles of neoadjuvant nivolumab + chemotherapy?

Topics: Lung Cancer • Thoracic Malignancies • Medical Oncology

Answer from: Medical Oncologist at Community Practice

Approximately, 1/4 (24%) of patients in the CheckMate 816 trial treated with nivolumab + chemotherapy achieved a pathologic CR (compared to 2% with neoadjuvant chemo alone). The patients who did achieve a pathCR had the best EFS (although limited follow up to date; median EFS not reached, HR 0.13). ...

Comments

Medical Oncologist at Alvin & Lois Lapidus Cancer Institute Northwest Hospital
Could you elaborate on your approach to the remain...

Answer from: Medical Oncologist at Academic Institution

I agree and follow the CheckMate 816 protocol and would observe patients with routine surveillance following completion of neoadjuvant therapy and surgery. The unknown, pending further data, is the impact of additional therapy? Since we cannot know, we risk overtreatment by giving both neoadjuvant a...

Answer from: Medical Oncologist at Community Practice

Related Questions